Reorg coming for little biotech as it shutters PhII radioimmunotherapy trial on underwhelming data

Amber Tong

After deciding that its radioimmunotherapy no longer has a viable path to commercialization, Norway’s Nordic Nanovector is shutting down its lead and only clinical trial …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Reorg coming for little biotech as it shutters PhII radioimmunotherapy trial on underwhelming data

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Post-Hoc: Pharma CEOs' alternative reality with Trump

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

How AI can address ongoing challenges in the life sciences industry

Re­org com­ing for lit­tle biotech as it shut­ters PhII ra­dioim­munother­a­py tri­al on un­der­whelm­ing da­ta

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Reorg coming for little biotech as it shutters PhII radioimmunotherapy trial on underwhelming data